Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Japan Launches Pilot Expert Committee System for Patent Linkage Reviews, Aims to Reduce IP Feuds
November 17, 2025
-
COMMENTARY MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
-
REGULATORY Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
-
BUSINESS Fuji Stresses No Supply Impact, Denies Patent Allegations over Eylea Biosimilar
November 17, 2025
-
REGULATORY Elrexfio to Escape CEA-Based Price Tweak, Analysis to Resume for Paxlovid
November 17, 2025
-
BUSINESS Novartis Overhauls Sales Model to Prioritize Solving Regional Treatment Gaps
November 14, 2025
-
REGULATORY Nipro-Samsung Alliance Nears First Approval in Japan with Stelara Biosimilar
November 14, 2025
-
REGULATORY Japan Panel to Review KalVista’s Oral HAE Drug, GSK’s Asthma Med, and More on Nov. 27
November 14, 2025
-
BUSINESS Keytruda Again Tops Japan Market in July-September: IQVIA
November 14, 2025
-
BUSINESS Bayer, Regeneron Move to Block Fuji’s Newly Listed Eylea Biosimilar in Japan
November 13, 2025
-
REGULATORY LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
November 12, 2025
-
BUSINESS J&J Japan Targets Top Share in Key Disease Areas by 2030: New President
November 12, 2025
-
REGULATORY Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
-
REGULATORY MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
-
REGULATORY Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
-
COMMENTARY Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
-
BUSINESS MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
-
REGULATORY MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
-
BUSINESS Novo Nordisk Taps Keisuke Kotani as New Japan Chief
November 7, 2025
-
REGULATORY Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…